Silence Therapeutics Plc ADR (SLN) Stock Price, Quote & News

Company Profile

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elev...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 3457 6900

Website: www.silence-therapeutics.com

Address:

12 Hammersmith Grove, London, United Kingdom

janed102 Aug. 11 at 8:42 PM

$SLN more dilution

0 · Reply

kshonstocks Aug. 11 at 7:24 PM

$SLN great opptnty here

0 · Reply

stockwitsuser2449 Aug. 11 at 6:19 PM

$SLN wait til after the offer closes if you are serious. even at the elevated prices..if they offered at the market price it is a 20% dilution...so instant share value drop to 12$....BUT they have in the past given shares at offers for about half the price so look closer to half that number if you are serious in considering this biotech.....they will however do this again..and again...and again so good luck ;)

1 · Reply

CapitalMonk Aug. 11 at 4:40 PM

$SLN Price: $15.65 (+1.43%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±4.06% RSI: 71.9 | Momentum: Strong Momentum Volume: -5.5% vs avg Volatility: 7.83% Support: $9.57 | Resistance: $17.58 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai

0 · Reply

SannieVerraderlijk Aug. 11 at 2:53 PM

$SLN Opened position at 15, will add if it dips on offering pricing

1 · Reply

MC_Hunter Aug. 11 at 1:09 PM

$SLN let’s go! This is a slower burn, but the data is super impressive! Should be in the 20s at least!

0 · Reply

kshonstocks Aug. 11 at 12:39 PM

Msco maintains ow on $SLN, tgt raised from 25 to 32

0 · Reply

itsBTK Aug. 11 at 12:16 PM

$SLN exactly

0 · Reply

kshonstocks Aug. 11 at 12:04 PM

$SLN v good data on watch on offering news

0 · Reply

laaarsas Aug. 11 at 11:27 AM

$SLN Totally missed by the market. With the results they just showed, this should be 25 bucks.

0 · Reply

Silence Therapeutics price target raised to $32 from $25 at Morgan Stanley

2026-08-10T20:35:32.000Z - 1 day ago

Silence Therapeutics files to sell $150M in ADS’s

Aug 10, 2026, 4:01 PM EDT - 1 day ago

Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares

Aug 10, 2026, 8:00 AM EDT - 1 day ago

Silence Therapeutics Transcript: Study result

Aug 10, 2026, 8:00 AM EDT - 1 day ago

Silence Therapeutics Press release: Study result

Aug 10, 2026, 8:00 AM EDT - 1 day ago

Silence Therapeutics Slides: Study result

2026-08-10T11:40:39.000Z - 1 day ago

Silence announces results from Phase 2 SANRECO trial met primary endpoint

Aug 10, 2026, 7:30 AM EDT - 1 day ago

Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

2026-08-10T11:20:17.000Z - 1 day ago

Silence Therapeutics reports Q2 EPS (9c), consensus (17c)

Aug 10, 2026, 7:15 AM EDT - 1 day ago

Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

Aug 10, 2026, 7:00 AM EDT - 1 day ago

Silence Therapeutics Earnings release: Q2 2026

Aug 10, 2026, 7:00 AM EDT - 1 day ago

Silence Therapeutics Quarterly report: Q2 2026

Aug 9, 2026, 5:00 PM EDT - 2 days ago

Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera

2026-07-14T20:35:20.000Z - 4 weeks ago

Silence Therapeutics participates in a conference call with Cantor

2026-07-14T20:05:16.000Z - 4 weeks ago

Silence Therapeutics participates in a conference call with William Blair

2026-06-24T10:55:08.000Z - 6 weeks ago

Cantor starts ‘materially undervalued’ Silence Therapeutics at Overweight

2026-06-24T10:10:31.000Z - 6 weeks ago

Silence Therapeutics initiated with an Overweight at Cantor Fitzgerald

Jun 23, 2026, 7:00 AM EDT - 7 weeks ago

Silence Therapeutics Slides: Corporate presentation

2026-06-11T11:36:45.000Z - 2 months ago

Silence Therapeutics highlights follow-up data on divesiran at EHA 2026

Jun 11, 2026, 7:30 AM EDT - 2 months ago

Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

Jun 3, 2026, 4:55 PM EDT - 2 months ago

Silence Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 27, 2026, 8:00 AM EDT - 2 months ago

Silence Therapeutics to Participate in Jefferies Global Healthcare Conference

May 19, 2026, 2:00 PM EDT - 3 months ago

Silence Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

2026-05-18T20:16:33.000Z - 3 months ago

Silence Therapeutics files $300M ordinary shares offering

May 18, 2026, 8:00 AM EDT - 3 months ago

Silence Therapeutics Registration statement: Registration filing

May 12, 2026, 8:00 AM EDT - 3 months ago

Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference

2026-05-08T08:30:11.000Z - 3 months ago

Silence Therapeutics price target lowered to $27 from $35 at Chardan

2026-05-07T13:21:52.000Z - 3 months ago

Silence Therapeutics reports Q1 EPS (11c) vs. (20c) last year

May 7, 2026, 8:00 AM EDT - 3 months ago

Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results

May 7, 2026, 8:00 AM EDT - 3 months ago

Silence Therapeutics Earnings release: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Silence Therapeutics Quarterly report: Q1 2026

May 6, 2026, 7:00 AM EDT - 3 months ago

Silence Therapeutics Slides: Corporate presentation

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Silence Therapeutics Proxy statement: Proxy filing

Mar 5, 2026, 7:30 AM EST - 5 months ago

Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 5, 2026, 7:30 AM EST - 5 months ago

Silence Therapeutics Annual report: Q4 2025

Mar 5, 2026, 7:30 AM EST - 5 months ago

Silence Therapeutics Earnings release: Q4 2025

Mar 5, 2026, 7:30 AM EST - 5 months ago

Silence Therapeutics Annual report: Q4 2025

2025-12-15T13:20:39.000Z - 8 months ago

Silence Therapeutics CEO Craig Tooman to end employment

Dec 15, 2025, 8:13 AM EST - 8 months ago

Silence Therapeutics Announces Leadership Changes

Nov 19, 2025, 8:00 AM EST - 9 months ago

Silence Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 8:00 AM EST - 9 months ago

Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference

2025-11-06T14:06:04.000Z - 9 months ago

Silence Therapeutics reports Q3 EPS (15c), consensus (21c)

Nov 6, 2025, 7:30 AM EST - 9 months ago

Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 7:30 AM EST - 9 months ago

Silence Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:30 AM EST - 9 months ago

Silence Therapeutics Earnings release: Q3 2025

2025-10-23T11:41:01.000Z - 10 months ago

Silence Therapeutics completes patient enrollment in SANRECO

Oct 23, 2025, 7:30 AM EDT - 10 months ago

Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)

Sep 9, 2025, 5:35 PM EDT - 1 year ago

Silence Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 2, 2025, 8:00 AM EDT - 1 year ago

Silence Therapeutics to Participate in September Investor Conferences

2025-08-07T12:37:16.000Z - 1 year ago

Silence Therapeutics reports Q2 EPS (19c), consensus (21c)

Aug 7, 2025, 7:30 AM EDT - 1 year ago

Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 7, 2025, 7:30 AM EDT - 1 year ago

Silence Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 7:30 AM EDT - 1 year ago

Silence Therapeutics Earnings release: Q2 2025

2025-06-12T20:05:13.000Z - 1 year ago

Silence Therapeutics presents additional Phase 1 data highlighting Divesiran

Jun 12, 2025, 4:01 PM EDT - 1 year ago

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

May 16, 2025, 8:00 AM EDT - 1 year ago

Silence Therapeutics Proxy statement: Proxy Filing

2025-05-08T12:35:24.000Z - 1 year ago

Silence Therapeutics reports Q1 EPS (20c), consensus (41c)

May 8, 2025, 8:00 AM EDT - 1 year ago

Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 8, 2025, 7:00 AM EDT - 1 year ago

Silence Therapeutics Quarterly report: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Silence Therapeutics Earnings release: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Silence Therapeutics Proxy statement: Proxy Filing

May 6, 2025, 7:45 AM EDT - 1 year ago

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

Mar 12, 2025, 1:00 PM EDT - 1 year ago

Silence Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 5, 2025, 8:00 AM EST - 1 year ago

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

Feb 27, 2025, 8:00 AM EST - 1 year ago

Silence Therapeutics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Silence Therapeutics Annual report: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Silence Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Silence Therapeutics Slides: Q4 2024

Feb 27, 2025, 7:30 AM EST - 1 year ago

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Feb 13, 2025, 8:00 AM EST - 1 year ago

Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

Dec 9, 2024, 7:30 AM EST - 1 year ago

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

Dec 4, 2024, 10:00 AM EST - 1 year ago

Silence Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 2:00 AM EST - 1 year ago

Silence Therapeutics Earnings release: Q3 2024

Nov 20, 2024, 9:00 AM EST - 1 year ago

Silence Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 2:30 PM EST - 1 year ago

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

Nov 14, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 13, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Sep 30, 2024, 9:00 AM EDT - 2 years ago

Silence Therapeutics Transcript: Chardan Genetic Medicines Conference

Sep 17, 2024, 10:20 AM EDT - 2 years ago

Silence Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2024, 11:30 AM EDT - 2 years ago

Silence Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 5, 2024, 5:35 PM EDT - 2 years ago

Silence Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 27, 2024, 8:00 AM EDT - 2 years ago

Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences

Aug 15, 2024, 8:00 AM EDT - 2 years ago

Silence Therapeutics Earnings release: Q2 2024

Aug 15, 2024, 7:30 AM EDT - 2 years ago

Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jun 27, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics Transcript: Study Result

Jun 27, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics Press release: Study Result

Jun 27, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics Slides: Study Result

Jun 27, 2024, 7:30 AM EDT - 2 years ago

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Jun 24, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration

Jun 20, 2024, 7:30 AM EDT - 2 years ago

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)

May 30, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics to Present at Jefferies Global Healthcare Conference

May 16, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

May 16, 2024, 7:00 AM EDT - 2 years ago

Silence Therapeutics Earnings release: Q1 2024

May 7, 2024, 8:00 AM EDT - 2 years ago

Silence Therapeutics Registration statement: Registration Filing

Apr 30, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Apr 29, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

Apr 8, 2024, 11:48 AM EDT - 2 years ago

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Silence Therapeutics Earnings Call Transcript: Q4 2023

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Silence Therapeutics Annual report: Q4 2023

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Silence Therapeutics Earnings release: Q4 2023

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Silence Therapeutics Slides: Q4 2023

Mar 13, 2024, 7:05 AM EDT - 2 years ago

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Mar 13, 2024, 7:00 AM EDT - 2 years ago

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Feb 28, 2024, 8:00 AM EST - 2 years ago

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

Feb 23, 2024, 8:00 AM EST - 2 years ago

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

Feb 5, 2024, 8:00 AM EST - 2 years ago

Silence Therapeutics Announces Oversubscribed $120 Million Private Placement

Jan 31, 2024, 7:00 AM EST - 2 years ago

Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Dec 1, 2023, 7:00 AM EST - 2 years ago

Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments

Nov 14, 2023, 7:00 AM EST - 2 years ago

Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

Nov 14, 2023, 7:00 AM EST - 2 years ago

Silence Therapeutics Earnings release: Q3 2023

Nov 13, 2023, 12:00 PM EST - 2 years ago

Silence Therapeutics Transcript: Study Update

Nov 8, 2023, 7:00 AM EST - 2 years ago

Silence Therapeutics to Present at Jefferies London Healthcare Conference

Nov 1, 2023, 7:00 AM EDT - 3 years ago

Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

Sep 26, 2023, 7:00 AM EDT - 3 years ago

Silence Therapeutics to Participate in Fireside Chat at Chardan's 7th Annual Genetic Medicines Conference

Sep 11, 2023, 9:20 AM EDT - 3 years ago

Silence Therapeutics Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Aug 16, 2023, 7:00 AM EDT - 3 years ago

Silence Therapeutics Reports Second Quarter 2023 Results

Aug 16, 2023, 7:00 AM EDT - 3 years ago

Silence Therapeutics Earnings release: Q2 2023

Jul 11, 2023, 7:00 AM EDT - 3 years ago

Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration

May 31, 2023, 7:00 AM EDT - 3 years ago

Silence Therapeutics to Present at the Jefferies Healthcare Conference

janed102 Aug. 11 at 8:42 PM

$SLN more dilution

0 · Reply

kshonstocks Aug. 11 at 7:24 PM

$SLN great opptnty here

0 · Reply

stockwitsuser2449 Aug. 11 at 6:19 PM

1 · Reply

CapitalMonk Aug. 11 at 4:40 PM

0 · Reply

SannieVerraderlijk Aug. 11 at 2:53 PM

$SLN Opened position at 15, will add if it dips on offering pricing

1 · Reply

MC_Hunter Aug. 11 at 1:09 PM

$SLN let’s go! This is a slower burn, but the data is super impressive! Should be in the 20s at least!

0 · Reply

kshonstocks Aug. 11 at 12:39 PM

Msco maintains ow on $SLN, tgt raised from 25 to 32

0 · Reply

itsBTK Aug. 11 at 12:16 PM

$SLN exactly

0 · Reply

kshonstocks Aug. 11 at 12:04 PM

$SLN v good data on watch on offering news

0 · Reply

laaarsas Aug. 11 at 11:27 AM

$SLN Totally missed by the market. With the results they just showed, this should be 25 bucks.

0 · Reply

TNNStockAnalysisNews Aug. 11 at 3:32 AM

0 · Reply

MadMaverick Aug. 11 at 2:12 AM

WATCHLIST RECAP $AUUD $SLN $ZJYL $TENX Slow day overall, none with big gains.

0 · Reply

FlipEm Aug. 10 at 9:25 PM

$SLN offering news out, price TBD

0 · Reply

BioTuesdays Aug. 10 at 8:45 PM

$SLN has announced positive topline results from the Phase 2 SANRECO trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with polycythemia vera (PV). https://biotuesdays.com/2026/08/10/silence-reveals-positive-topline-results-from-trial-of-divesiran-in-pv/

0 · Reply

stockwitsuser2449 Aug. 10 at 8:26 PM

$SLN offering

0 · Reply

JeremyDanie Aug. 10 at 8:21 PM

$SLN https://www.businesswire.com/news/home/20260810617219/en/Silence-Therapeutics-Announces-Proposed-Public-Offering-of-%24150-Million-of-American-Depositary-Shares

0 · Reply

masonat Aug. 10 at 7:10 PM

$SLN Sold this morning on the pop but might have to buy back in if this continues lower. Takeda seeing 1.5B peak for rusfertide and this seems superior on both response rate and dosing. Then you have pelacarsen readout any day now (sometime in the next three months I'd guess) which provides another shot on goal. Don't think their lp(a) asset is very differentiated but it's better than pelacarsen and market might reward them for HORIZON success.

1 · Reply

stockwitsuser2449 Aug. 10 at 6:15 PM

$SLN careful...

1 · Reply

laaarsas Aug. 10 at 4:44 PM

$SLN This price action is ridicoulous. We should be way higher. Just wait and see I guess.

0 · Reply

prismmarketview Aug. 10 at 4:18 PM

PRISM Mid-Day Movers: New Energy and Global Health are Today’s Leaders. 5E Advanced Materials, Inc. (NASDAQ: $FEAM ) is surging today, with the stock up about 40% from Friday’s 1.50 close as buyers pile into the boron‑materials developer. Silence Therapeutics plc (NASDAQ: $SLN ) is surging today, with the stock up roughly 34% to 16.13 after closing at 11.95 on Friday. Other Notable Movers: Innate Pharma S.A. ( $IPHA) up 24% AgEagle Aerial Systems, Inc. ( $UAVS) up 16% Vertical Aerospace Ltd. ( $EVTL ) down -34% https://prismmarketview.com/prism-mid-day-movers-new-energy-and-global-health-are-todays-leaders/

0 · Reply

BearTamerTradingLLC Aug. 10 at 4:14 PM

My Top Trades 8.10.26 $SCKT $PCLA $STKH $SLN $ACHR Got a few others as well, super great day for retail. Please watch video below for proof 👇🏽 (turn on sound) https://www.youtube.com/channel/UCfsmfz5F8NRG4H70oOK1CNA/join

0 · Reply

Qtobeone Aug. 10 at 3:23 PM

$SLN

0 · Reply

Market Cap	728.84M
Revenue (ttm)	560,000.00
Net Income (ttm)	-88.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-15,823.21%
Debt to Equity Ratio	0.00

Volume	3,289,300
Avg Vol	881,118
Day's Range	N/A - N/A
Shares Out	47.24M
Stochastic %K	61%
Beta	1.39
Analysts	Strong Sell
Price Target	$31.20